Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $50.7 million.

  • Anaptysbio's Total Non-Current Liabilities fell 1336.54% to $50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year decrease of 1336.54%. This contributed to the annual value of $59.5 million for FY2024, which is 1133.34% up from last year.
  • Per Anaptysbio's latest filing, its Total Non-Current Liabilities stood at $50.7 million for Q3 2025, which was down 1336.54% from $48.6 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Total Non-Current Liabilities ranged from a high of $59.5 million in Q4 2024 and a low of $35.5 million during Q4 2021
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $51.9 million (2023), whereas its average is $49.7 million.
  • Per our database at Business Quant, Anaptysbio's Total Non-Current Liabilities surged by 7935.02% in 2021 and then plummeted by 1336.54% in 2025.
  • Quarter analysis of 5 years shows Anaptysbio's Total Non-Current Liabilities stood at $35.5 million in 2021, then increased by 23.4% to $43.9 million in 2022, then grew by 21.91% to $53.5 million in 2023, then increased by 11.33% to $59.5 million in 2024, then fell by 14.9% to $50.7 million in 2025.
  • Its Total Non-Current Liabilities was $50.7 million in Q3 2025, compared to $48.6 million in Q2 2025 and $57.6 million in Q1 2025.